Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus Platinum in mHSPC with DNA Repair Mutation
NCT05461261Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jul 2022
- Primary completion
- Jun 2025
- Modality
- Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Cisplatin micelle injection (HA132) and carboplatin in prostate cancer (PCa) (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Time to Metastatic Castration-Resistant Prostate Cancer at 3 years. Started Jul 2022; status: recruiting.
02
Drugs
Cisplatin micelle injection (HA132)carboplatin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05461261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05461261.